Phio Pharma up after H.C. Wainwright assumes coverage with 'buy' rating
View all comments(0)
Shares of drug developer Phio Pharmaceuticals PHIO.O rises 12.4% to $2.36 premarket
Brokerage H.C. Wainwright assumes coverage with "buy" rating; sets PT at $14
New PT represents a near seven-fold increase from the stock's last close
"We believe Phio is flying under the radar with investors, and we have a bullish outlook for the stock" - H.C. Wainwright
Says co's lead asset skin cancer therapy, PH-762, has already showed "impressive clinical activity and exhibited favorable safety in an early-stage study"
Brokerage says it believes remaining open to partnering opportunities is "an underappreciated position in current market conditions"
As of last close, stock up 16.7% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
April 2026 CPI Preview: Will Hot Inflation Crush Nasdaq, S&P 500 & NVDA? Explosive Market Reaction Guide

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

Tradingkey






Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.